BriaCell’s pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration (FDA). “We are pleased with the DSMB’s recommendation for the ...

DSMB recommends continuing Phase 3 DRAGON ... global Phase 3 “DRAGON” trial data of Tinlarebant in adolescent Stargardt disease patients, the Data Safety Monitoring Board (DSMB) has ...

In this phase 3, double-blind, randomized ... was approved by the institutional review board or independent ethics committee at each site. All the participants provided written informed consent ...